Abstract:In recent years, clustered regularly interspaced short palindromic repeats (CRISPRs) and CRISPR-associated (Cas) protein have emerged as a revolutionary gene editing tool to treat inherited disorders affecting different organ systems, such as blood and muscles. Both hematological and neuromuscular genetic disorders benefit from genome editing approaches but face different challenges in their clinical translation. The ability of CRISPR/Cas9 technologies to modify hematopoietic stem cells ex vivo has greatly accelerated the development of genetic therapies for blood disorders. In the last decade, many clinical trials were initiated and are now delivering encouraging results. The recent FDA approval of Casgevy, the first CRISPR/Cas9-based drug for severe sickle cell disease and transfusion-dependent β-thalassemia, represents a significant milestone in the field and highlights the great potential of this technology. Similar preclinical efforts are currently expanding CRISPR therapies to other hematologic disorders such as primary immunodeficiencies. In the neuromuscular field, the versatility of CRISPR/Cas9 has been instrumental for the generation of new cellular and animal models of Duchenne muscular dystrophy (DMD), offering innovative platforms to speed up preclinical development of therapeutic solutions. Several corrective interventions have been proposed to genetically restore dystrophin production using the CRISPR toolbox and have demonstrated promising results in different DMD animal models. Although these advances represent a significant step forward to the clinical translation of CRISPR/Cas9 therapies to DMD, there are still many hurdles to overcome, such as in vivo delivery methods associated with high viral vector doses, together with safety and immunological concerns. Collectively, the results obtained in the hematological and neuromuscular fields emphasize the transformative impact of CRISPR/Cas9 for patients affected by these debilitating conditions. As each field suffers from different and specific challenges, the clinical translation of CRISPR therapies may progress differentially depending on the genetic disorder. Ongoing investigations and clinical trials will address risks and limitations of these therapies, including long-term efficacy, potential genotoxicity, and adverse immune reactions. This review provides insights into the diverse applications of CRISPR-based technologies in both preclinical and clinical settings for monogenic blood disorders and muscular dystrophy and compare advances in both fields while highlighting current trends, difficulties, and challenges to overcome.

Gene Editing of Hematopoietic Stem Cells: Hopes and Hurdles Toward Clinical Translation

Hematopoietic stem and progenitors cells gene editing: Beyond blood disorders

Advances and Obstacles in Homology-Mediated Gene Editing of Hematopoietic Stem Cells

Genome Editing Therapy for the Blood: Ex Vivo Success and In Vivo Prospects

Current approaches and potential challenges in the delivery of gene editing cargos into hematopoietic stem and progenitor cells

Therapy Development by Genome Editing of Hematopoietic Stem Cells

Base Editors-Mediated Gene Therapy in Hematopoietic Stem Cells for Hematologic Diseases

Homology-directed gene-editing approaches for hematopoietic stem and progenitor cell gene therapy

Therapeutic Gene Editing for Hemoglobinopathies

Gene therapy using haematopoietic stem and progenitor cells

Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins

CRISPR-Based Gene Therapies: From Preclinical to Clinical Treatments

Advancements in Hematopoietic Stem Cell Gene Therapy: A Journey of Progress for Viral Transduction

Comprehensive Update on Applications of CRISPR / Cas 9 for Hematological Diseases

The CRISPR-Cas System and Clinical Applications of CRISPR-Based Gene Editing in Hematology with a Focus on Inherited Germline Predisposition to Hematologic Malignancies

Homology-Directed-Repair-Based Genome Editing in HSPCs for the Treatment of Inborn Errors of Immunity and Blood Disorders

Automated Good Manufacturing Practice-Compatible CRISPR-Cas9 Editing of Hematopoietic Stem and Progenitor Cells for Clinical Treatment of β-Hemoglobinopathies

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications.

Near-perfect precise on-target editing of human hematopoietic stem and progenitor cells

Hematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned